Defendant
1 case as defendant.
Company Overview
Soleno Therapeutics, Inc. (NASDAQ: SLNO) is a publicly traded biopharmaceutical company headquartered in Redwood City, California. Founded in 1999 as Capnia, Inc., the company rebranded to its current name in May 2017. Soleno Therapeutics focuses on developing and commercializing novel treatments for rare diseases. As of early 2026, the company has approximately 182 employees and a market capitalization of around $2.7 billion. For the full year ending December 31, 2025, the company reported net product revenue of $190.4 million.
Products and Operations
Soleno's primary focus is on therapies for rare metabolic and neurobehavioral disorders. The company's lead product is VYKAT™ XR (diazoxide choline) extended-release tablets, a once-daily oral treatment. This product is the first FDA-approved therapy for the treatment of hyperphagia (an abnormally strong, persistent sensation of hunger) in adults and children aged four and older with Prader-Willi syndrome (PWS), a rare and complex genetic disorder. The company is also evaluating diazoxide choline for potential use in other rare diseases.
Patent Litigation Posture
As an operating biopharmaceutical company, Soleno Therapeutics appears in the provided database as a defendant in patent-related proceedings. The single tracked case is an action filed against it by Apotex Inc. at the Patent Trial and Appeal Board (PTAB). This posture, with zero cases as a plaintiff and one as a defendant, is typical for a commercial-stage drug developer facing challenges from other pharmaceutical companies, rather than a patent assertion entity.
Notable Cases and Context
The tracked case, Apotex Inc. v. Soleno Therapeutics Inc., was filed at the PTAB in April 2026. This type of proceeding often involves challenges to the validity of a company's patents. While details of this specific case are not elaborated, it is common for pharmaceutical companies like Apotex, which often develops generic drugs, to challenge the patents of brand-name drug manufacturers. Separately, Soleno has faced a securities class action lawsuit filed in 2026, alleging the company failed to disclose safety concerns related to its lead product during clinical trials.
An inter partes review (IPR) filed by petitioner Apotex Inc. against patent owner Soleno Therapeutics Inc. The proceeding is pending before the Patent Trial and Appeal Board.